Melphalan
- Generic Name
- Melphalan
- Brand Names
- Alkeran, Evomela, Phelinun, Pepaxti
- Drug Type
- Small Molecule
- Chemical Formula
- C13H18Cl2N2O2
- CAS Number
- 148-82-3
- Unique Ingredient Identifier
- Q41OR9510P
- Background
Melphalan is a nitrogen mustard or bischloroethylamine type alkylating agent. It was first synthesized in the early 1950s by substituting L-phenylalanine for the methyl group on nitrogen mustard. Melphalan is used in the treatment of multiple myeloma and ovarian carcinoma. It is also used for high-conditioning before hematopoietic stem cell transplant. It is also used to treat uveal melanoma with unresectable hepatic metastases.
- Indication
Melphalan is indicated for use as a high-dose conditioning treatment prior to hematopoietic stem cell transplantation in patients with multiple myeloma. It is also indicated for the palliative treatment of multiple myeloma and for the palliation of non-resectable epithelial carcinoma of the ovary.
Melphalan is a component of HEPZATO KIT, a liver-directed therapy indicated for the treatment of adults with uveal melanoma with unresectable hepatic metastases affecting less than 50% of the liver and no extrahepatic disease or extrahepatic disease limited to the bone, lymph nodes, subcutaneous tissues, or lung that is amenable to resection or radiation.
- Associated Conditions
- Multiple Myeloma (MM), Unresectable Liver Metastasis, Unresectable Ovarian Cancer (Epithelial)
- Associated Therapies
- Conditioning regimens for allogeneic stem cell transplantation therapy
High Dose Therapy and Autologous Stem Cell Transplantation Followed by Infusion of Chimeric Antigen Receptor (CAR) Modified T-Cells Directed Against CD19+ B-Cells for Relapsed and Refractory Aggressive B Cell Non-Hodgkin Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2013-04-25
- Last Posted Date
- 2024-05-29
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Target Recruit Count
- 17
- Registration Number
- NCT01840566
- Locations
- 🇺🇸
Memorial Sloan Kettering Commack (Limited protocol activities), Commack, New York, United States
🇺🇸Memorial Sloan Kettering Westchester (Limited Protocol Activities), Harrison, New York, United States
🇺🇸Memorial Sloan Kettering Cancer Center, New York, New York, United States
Busulfan, Cyclophosphamide, and Melphalan or Busulfan and Fludarabine Phosphate Before Donor Hematopoietic Cell Transplant in Treating Younger Patients With Juvenile Myelomonocytic Leukemia
- Conditions
- Interventions
- First Posted Date
- 2013-04-05
- Last Posted Date
- 2018-12-05
- Lead Sponsor
- Children's Oncology Group
- Target Recruit Count
- 30
- Registration Number
- NCT01824693
- Locations
- 🇺🇸
Rainbow Babies and Childrens Hospital, Cleveland, Ohio, United States
🇺🇸Mattel Children's Hospital UCLA, Los Angeles, California, United States
🇺🇸City of Hope Comprehensive Cancer Center, Duarte, California, United States
Phase 3 Study of Carfilzomib, Melphalan, Prednisone vs Bortezomib, Melphalan, Prednisone in Newly Diagnosed Multiple Myeloma
- Conditions
- Interventions
- First Posted Date
- 2013-03-26
- Last Posted Date
- 2019-08-26
- Lead Sponsor
- Amgen
- Target Recruit Count
- 955
- Registration Number
- NCT01818752
- Locations
- 🇺🇸
California Cancer Associates for Research & Excellence, Inc. (cCARE), Fresno, California, United States
🇨🇳Guangdong General Hospital, Guangzhou, Guangdong, China
🇦🇺The Alfred Hospital, Melbourne, Victoria, Australia
Targeting the IPA and Matching for the Non-Inherited Maternal Antigen for Haplo-Cord Transplantation
- First Posted Date
- 2013-03-13
- Last Posted Date
- 2024-10-09
- Lead Sponsor
- Weill Medical College of Cornell University
- Target Recruit Count
- 270
- Registration Number
- NCT01810588
- Locations
- 🇺🇸
Weill Cornell Medical College, New York, New York, United States
🇺🇸University of Chicago Medical Center, Chicago, Illinois, United States
Pomalidomide With Melphalan and Dexamethasone for Untreated Systemic AL Amyloidosis
- Conditions
- Interventions
- First Posted Date
- 2013-03-08
- Last Posted Date
- 2016-05-13
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 3
- Registration Number
- NCT01807286
- Locations
- 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States
Haploidentical Donor Hematopoietic Progenitor Cell and NK Cell Transplantation for Hematologic Malignancy
- First Posted Date
- 2013-03-08
- Last Posted Date
- 2022-10-31
- Lead Sponsor
- St. Jude Children's Research Hospital
- Target Recruit Count
- 82
- Registration Number
- NCT01807611
- Locations
- 🇺🇸
St. Jude Children's Research Hospital, Memphis, Tennessee, United States
Reduced Intensity Haploidentical BMT for High Risk Solid Tumors
- First Posted Date
- 2013-03-05
- Last Posted Date
- 2024-06-21
- Target Recruit Count
- 60
- Registration Number
- NCT01804634
- Locations
- 🇺🇸
Albert Einstein College of Medicine, Children's Hospital at Montefiore, Bronx, New York, United States
🇺🇸New York Medical Center/ Maria Fareri Children's Hospital, Valhalla, New York, United States
🇺🇸Johns Hopkins All Children's Hospital, Saint Petersburg, Florida, United States
Busulfan, Melphalan, and Stem Cell Transplant After Chemotherapy in Treating Patients With Newly Diagnosed High-Risk Neuroblastoma
- Conditions
- Interventions
- Procedure: Autologous Hematopoietic Stem Cell TransplantationDrug: BusulfanDrug: CisplatinDrug: CyclophosphamideDrug: Doxorubicin HydrochlorideDrug: EtoposideRadiation: External Beam Radiation TherapyBiological: FilgrastimOther: Laboratory Biomarker AnalysisDrug: MelphalanDrug: MesnaProcedure: Peripheral Blood Stem Cell TransplantationOther: Pharmacological StudyDrug: Topotecan HydrochlorideDrug: Vincristine Sulfate
- First Posted Date
- 2013-02-25
- Last Posted Date
- 2024-07-15
- Lead Sponsor
- Children's Oncology Group
- Target Recruit Count
- 150
- Registration Number
- NCT01798004
- Locations
- 🇺🇸
Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States
🇨🇦Hospital for Sick Children, Toronto, Ontario, Canada
🇺🇸Memorial Regional Hospital/Joe DiMaggio Children's Hospital, Hollywood, Florida, United States
Phase 1-2 Study of Total Bone Marrow Irradiation With Helicoidal Tomotherapy in 1st Myeloma Relapse
- Conditions
- Interventions
- First Posted Date
- 2013-02-20
- Last Posted Date
- 2021-01-22
- Lead Sponsor
- Institut Cancerologie de l'Ouest
- Target Recruit Count
- 13
- Registration Number
- NCT01794572
- Locations
- 🇫🇷
CLCC ICO, service de radiothérapie, Saint-Herblain, France
🇫🇷CHU Haut-Leveque, service d'Hématologie, Bordeaux, France
🇫🇷CLCC Bergonie, service de radiotherapie, Bordeaux, France
Whole-Body Radiation Therapy, Systemic Chemotherapy, and High-Dose Chemotherapy Followed By Stem Cell Rescue in Treating Patients With Poor-Risk Ewing Sarcoma
- Conditions
- Recurrent Childhood Supratentorial Primitive Neuroectodermal TumorEwing Sarcoma of BoneMetastatic Ewing Sarcoma/Peripheral Primitive Neuroectodermal TumorAdult Supratentorial Primitive Neuroectodermal Tumor (PNET)Extraosseous Ewing SarcomaUntreated Childhood Supratentorial Primitive Neuroectodermal TumorRecurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor
- Interventions
- Drug: etoposideDrug: ifosfamideRadiation: intensity-modulated radiation therapyDrug: topotecan hydrochlorideDrug: busulfanDrug: melphalanProcedure: autologous hematopoietic stem cell transplantationProcedure: peripheral blood stem cell transplantationProcedure: autologous bone marrow transplantation
- First Posted Date
- 2013-02-20
- Last Posted Date
- 2015-01-09
- Lead Sponsor
- City of Hope Medical Center
- Registration Number
- NCT01795430
- Locations
- 🇺🇸
City of Hope Medical Center, Duarte, California, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.